EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice

Kenta Motomura iD, Akifumi Kuwano, Kosuke Tanaka, Yuta Koga, Akihide Masumoto, Masayoshi Yada iD

Cancers · 30.08.2023 · 15 (17) · 4345

DOI: 10.3390/cancers15174345 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.08.2023. Verfasst von Kenta Motomura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the systemic drug treatment of hepatocellular carcinoma, only the tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This was followed by the development of regorafenib as a second-line treatment after sorafenib, and then lenvatinib, a new TKI, proved non-inferiority to sorafenib and became available as a first-line treatment. Subsequently, cabozantinib, another TKI, was introduced as a second-line treatment, along with ramucirumab, the only drug proven to be predictive of therapeutic efficacy when AFP levels are >400 ng/mL. It is an anti-VEGF receptor antibody. More recently, immune checkpoint inhibitors have become the mainstay of systemic therapy and can now be used as a first-line standard treatment for HCC. However, the objective response rate for these drugs is currently only 30% to 40%, and there is a high incidence of side effects. Additionally, there are no practical biomarkers to predict their therapeutic effects. Therefore, this review provides an overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation.

Schlagwörter

Stichwörter der Autor:innen

biomarkershepatocellular carcinomaimmune checkpoint inhibitorstyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan.

ORCID-Profile: Kenta Motomura, Masayoshi Yada

Zitieren

APA

Motomura, K., Kuwano, A., Tanaka, K., Koga, Y., Masumoto, A., & Yada, M. (2023). Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers, 15(17), 4345. https://doi.org/10.3390/cancers15174345

Vancouver

Motomura K, Kuwano A, Tanaka K, Koga Y, Masumoto A, Yada M. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers. 2023;15(17):4345. doi:10.3390/cancers15174345

BibTeX
@article{Motomura2023,
  author = {Motomura, Kenta and Kuwano, Akifumi and Tanaka, Kosuke and Koga, Yuta and Masumoto, Akihide and Yada, Masayoshi},
  title = {Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {17},
  pages = {4345},
  doi = {10.3390/cancers15174345}
}
Kostenlos starten →